Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.
Moldt B, Parvangada A, Martin R, Pace C, Balakrishnan M, Thomsen ND, E Collins S, Kuster H, Braun DL, Günthard HF, Geleziunas R, Callebaut C. Moldt B, et al. Among authors: balakrishnan m. J Acquir Immune Defic Syndr. 2021 Sep 1;88(1):61-69. doi: 10.1097/QAI.0000000000002722. J Acquir Immune Defic Syndr. 2021. PMID: 34397744
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.
Sloan DD, Lam CY, Irrinki A, Liu L, Tsai A, Pace CS, Kaur J, Murry JP, Balakrishnan M, Moore PA, Johnson S, Nordstrom JL, Cihlar T, Koenig S. Sloan DD, et al. Among authors: balakrishnan m. PLoS Pathog. 2015 Nov 5;11(11):e1005233. doi: 10.1371/journal.ppat.1005233. eCollection 2015. PLoS Pathog. 2015. PMID: 26539983 Free PMC article.
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T. Wei DG, et al. Among authors: balakrishnan m. PLoS Pathog. 2014 Apr 10;10(4):e1004071. doi: 10.1371/journal.ppat.1004071. eCollection 2014 Apr. PLoS Pathog. 2014. PMID: 24722454 Free PMC article. Clinical Trial.
Author Correction: A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.
Xie X, Muruato AE, Zhang X, Lokugamage KG, Fontes-Garfias CR, Zou J, Liu J, Ren P, Balakrishnan M, Cihlar T, Tseng CK, Makino S, Menachery VD, Bilello JP, Shi PY. Xie X, et al. Among authors: balakrishnan m. Nat Commun. 2021 Jun 21;12(1):3984. doi: 10.1038/s41467-021-24300-8. Nat Commun. 2021. PMID: 34155200 Free PMC article. No abstract available.
RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information.
Kirschberg TA, Balakrishnan M, Squires NH, Barnes T, Brendza KM, Chen X, Eisenberg EJ, Jin W, Kutty N, Leavitt S, Liclican A, Liu Q, Liu X, Mak J, Perry JK, Wang M, Watkins WJ, Lansdon EB. Kirschberg TA, et al. Among authors: balakrishnan m. J Med Chem. 2009 Oct 8;52(19):5781-4. doi: 10.1021/jm900597q. J Med Chem. 2009. PMID: 19791799
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.
Xie X, Muruato AE, Zhang X, Lokugamage KG, Fontes-Garfias CR, Zou J, Liu J, Ren P, Balakrishnan M, Cihlar T, Tseng CK, Makino S, Menachery VD, Bilello JP, Shi PY. Xie X, et al. Among authors: balakrishnan m. bioRxiv [Preprint]. 2020 Jun 23:2020.06.22.165712. doi: 10.1101/2020.06.22.165712. bioRxiv. 2020. Update in: Nat Commun. 2020 Oct 15;11(1):5214. doi: 10.1038/s41467-020-19055-7 PMID: 32607511 Free PMC article. Updated. Preprint.
284 results